Attention Deficit Hyperactivity Disorder Market Forecasts to 2028 – Global Analysis By medication (Stimulant, Non Stimulant and Other Medications), By Psychotherapy (Behaviour Therapy, Cognitive Behavioural Therapy and Other Psychotherapies), By Education Or Training (Social Skills Training, Parent Management Training and Other Education Or Trainings ), Distribution Channel and By Geography.
According to Stratistics MRC, the Global Attention Deficit Hyperactivity Disorder Market is accounted for $13.21 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 6.2% during the forecast period. Attention Deficit Hyperactivity Disorder is a chronic condition including attention difficulty, hyperactivity and impulsiveness. Attention deficit hyperactivity disorder often begins in childhood and can persist into adulthood. It may contribute to low self-esteem, troubled relationships and difficulty at school or work. Symptoms include limited attention and hyperactivity. There are many treatment options that works best can depend on the individual child and family.
According to the Centers for Diseases Control and Prevention, in September 2021, 8.8% of people have been diagnosed with attention deficit hyperactivity disorder at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis. In addition, increasing spending on the treatment of attention deficit hyperactivity disorder in the United States with rising prescription rates is expected to boost the market.
Market Dynamics:
Driver:
Rise in the incidence of attention deficit hyperactivity disorder
The causes of attention deficit hyperactivity disorder are still unclear, although genetic presence is observed in many cases. The incidence of this disorder is rising at a higher rate, which drives the global attention deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. Moreover, increasing attentiveness regarding the syndrome among physicians and patients and opinion-based due to the lack of regular diagnostic tests and, increasing advancements in the medical field, a growing number of researches in neurosciences, and raising awareness about mental illness among people are encouraging the market growth to a significant level.
Restraint:
Involving side effects
Attention deficit hyperactivity disorder medication has side effects such as loss of appetite and trouble sleeping. Other attention deficit hyperactivity disorder medicine side effects include nervousness, irritability, moodiness, headaches, stomachaches, fast heart rate, and high blood pressure. Side effects usually happen in the first few days of starting a new medicine or taking a higher dose these side effects can also be controlled by reducing the dose or changing the medication, due to which patients are not convinced in adopting to the medication treatment thus hindering the market growth.
Opportunity:
Increasing prevalence of attention deficit hyperactivity disorder
Even though the prevalence of the attention deficit hyperactivity disorder is not known this disorder is highly prevalent in many children all around the world, hence there is a major need for the advancement in the medical field and innovated products for the treatment of attention deficit hyperactivity disorder in the market moreover the growth in responsiveness about mental illness amongst people are the factors expected to boost the growth of the attention-deficit hyperactivity disorder market in the forecast period.
Threat:
High cost of medication
The high cost of attention deficit hyperactivity disorder medications, improper reimbursement policies, and side effects related to the medications such as insomnia, anorexia, dizziness, headaches, and mood changes are restraining the growth of the global attention deficit hyperactivity disorder therapeutics market. Moreover, all the side effects connected with the drugs affect the patients lives and hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period.
Covid-19 Impact
The Pandemic has had a lot of harmful impacts on people suffering from attention-deficit hyperactivity disorder. The major reason for the consequence is susceptibility, to the distress caused by the pandemic and physical distancing measures, owing to these factors, the patient can display increased behavioural problems. The increase in the issues will boost the sale of attention deficit hyperactivity disorder therapeutics, and the buying by consumers has finished the stock of the current batch of medicines and forced them to make a fresh batch. Moreover, hospital visits for non-essential medical conditions have been delayed, causing persons with attention deficit hyperactivity disorder to depend totally on drugs helping in boosting the market growth.
The Stimulant segment is expected to be the largest during the forecast period
The Stimulant segment is estimated to have a lucrative growth, due to its increased activity in the brain particularly in areas that play a part in controlling attention and behaviour. Various drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, etc are used in the treatment of Attention Deficit Hyperactivity Disorder. Amphetamines and methylphenidate are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder. They work quickly, and there is also a reduction in overall impulsivity and attention deficit hyperactivity disorder symptoms in two hours. The stimulants are the most effective treatment for attention deficit hyperactivity disorder patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of attention deficit hyperactivity disorder boosts the segment growth over the forecast period.
The Behaviour therapy segment is expected to have the highest CAGR during the forecast period
The Behaviour therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to effective treatment for attention deficit hyperactivity disorder that can improve a child's behaviour, self-control, and self-esteem. It is most helpful in young children when it is delivered by parents and is a short-term, goal-oriented form of psychotherapy that aims to change negative patterns of thinking and reframe the way a patient feels about herself and her symptoms of attention deficit hyperactivity disorder. Additionally, children benefit in the long term as they can apply the techniques any time they need to handle with negative emotions. Hence all the above factors contribute in the market growth.
Region with highest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to the displeased needs and large patient population, and even the ease of access of lower-cost drugs for attention deficit hyperactivity disorder treatment. In addition, factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence, private organizations and the bigger funding from the population are responsible for the regional market's growth. Also, the accessibility of new treatments and technology affects the growing demand and encourages the growth of the regional attention deficit hyperactivity disorder therapeutics market.
Region with highest CAGR:
Europe is projected to have the highest CAGR over the forecast period, owing to the growing alertness about the mental health and the increasing of the incidences of attention-deficit or hyperactivity disorder. Moreover, due to the large number of drug prescriptions, written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development. Furthermore, the high ingestion of additives and preservatives, and the improvising of the coverage for treatment of the condition which in turn are anticipated to further propel the growth of the attention-deficit hyperactivity market in the region in the coming years.
Key players in the market
Some of the key players profiled in the Attention Deficit Hyperactivity Disorder Market include Noven Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Neos Therapeutics, Inc., Supernus Pharmaceuticals, Novartis AG, Johnson & Johnson, Lilly, Pfizer Inc., Alcobra Ltd., Neurosigma, Inc, Hisamitsu Pharmaceutical Co.,Inc , KemPharm, Inc., Curemark, LLC., Mallinckrodt, UCB S.A, Purdue Pharma L.P. Actavis.
Key Developments:
In Nov 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.
In Oct 2022, Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy. Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China, a Phase 2b investigational therapy for the treatment of celiac disease.
In Jun 2022, Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa. The partnership with ASH will not only deliver better tools to track a baby’s diagnosis, but also support greater knowledge on treatment and care, including through publications on research findings, professional education and dissemination to policy makers and other audiences.
Medications Covered:
• Stimulant
• Non Stimulant
• Other Medications
Psychotherapies Covered:
• Behaviour Therapy
• Cognitive Behavioural Therapy
• Family Therapy
• Interpersonal Psychotherapy
• Other Psychotherapies
Education Or Trainings Covered:
• Social Skills Training
• Parent Management Training
• School-Based Interventions
• Other Education Or Trainings
Distribution Channels Covered:
• Retail Pharmacy
• Hospital Pharmacy
• Specialty Clinics
• E-Commerce
• Other Distribution Channels
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook